Navamedic Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Navamedic şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.5%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Is Navamedic (OB:NAVA) Using Too Much Debt?

Sep 19

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Feb 18

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Nov 09

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

Feb 18

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Dec 07

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NAVA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NAVA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Navamedic Piyasaya Karşı Temettü Getirisi

NAVA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NAVA)	n/a
Pazarın Alt %25'i (NO)	3.3%
Pazarın En İyi %25'i (NO)	7.6%
Sektör Ortalaması (Pharmaceuticals)	2.5%
Analist tahmini (NAVA) (3 yıla kadar)	0%

Önemli Temettü: NAVA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NAVA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NAVA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NAVA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Navamedic Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Consensus EPS estimates fall by 21%

Chief Financial Officer recently bought kr476k worth of stock

Navamedic Launches Eroxon in Finland

New minor risk - Profit margin trend

Third quarter 2024 earnings released

Investor sentiment deteriorates as stock falls 17%

Chief Executive Officer exercised options to buy kr2.2m worth of stock.

Consensus EPS estimates fall by 12%

Director recently bought kr1.5m worth of stock

Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023)

Price target decreased by 7.1% to kr45.50

First quarter 2024 earnings released

An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 28%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings released

Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024

Third quarter 2023 earnings released

Consensus EPS estimates increase by 10%

Is Navamedic (OB:NAVA) Using Too Much Debt?

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 53%

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 16%, revenue upgraded

Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors

First quarter 2023 earnings released

Price target increased by 8.7% to kr50.00

Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly

Full year 2022 earnings released

Consensus EPS estimates increase by 20%, revenue downgraded

Navamedic ASA Launches Modifast in Norway

Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023

Price target increased to kr48.00

No independent directors

Consensus EPS estimates increase by 19%

Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality

Third quarter 2022 earnings released

Is Navamedic (OB:NAVA) A Risky Investment?

Consensus forecasts updated

Price target decreased to kr44.00

Navamedic ASA Launches Forlaxgo®

Consensus EPS estimates increase by 50%

Consensus EPS estimates increase by 30%

Chief Financial Officer exercised options to buy kr2.1m worth of stock.

Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million .

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB.

Price target increased to kr50.00

No independent directors

Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden

Full year 2021 earnings: Revenues exceed analyst expectations

Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea

Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022

Third quarter 2021 earnings released

We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020)

Navamedic ASA Announces the Launch of New Products in the Nordics

Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden

First quarter 2021 earnings released

Is Navamedic (OB:NAVA) Using Too Much Debt?

New 90-day high: kr29.00

Full year 2020 earnings released

If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today

New 90-day high: kr22.60

Is Navamedic (OB:NAVA) Using Debt Sensibly?

Navamedic ASA to Report Q2, 2021 Results on Aug 13, 2021

New 90-day low: kr17.45

New 90-day low: kr18.20

Chief Executive Officer exercised options to buy kr2.3m worth of stock.

New 90-day low: kr18.50

Earnings released